Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib

Clin Breast Cancer. 2014 Feb;14(1):e14-6. doi: 10.1016/j.clbc.2013.09.010. Epub 2013 Sep 27.

Affiliations

¹ Foundation Medicine, Inc, Cambridge, MA.
² Department of Pathology.
³ Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA.
⁴ Foundation Medicine, Inc, Cambridge, MA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY.
⁵ Department of Pathology. Electronic address: [email protected].

PMID: 24201163
DOI: 10.1016/j.clbc.2013.09.010

No abstract available

Keywords: HER2; Inflammatory breast cancer; Lapatinib; Next-generation sequencing; Trastuzumab.

Publication types

Case Reports

MeSH terms

ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics*
Erlotinib Hydrochloride
Female
Humans
Inflammatory Breast Neoplasms / drug therapy*
Inflammatory Breast Neoplasms / genetics
Inflammatory Breast Neoplasms / pathology
Middle Aged
Mutation*
Protein Kinase Inhibitors / therapeutic use*
Quinazolines / therapeutic use*

Substances

Protein Kinase Inhibitors
Quinazolines
Erlotinib Hydrochloride
ErbB Receptors